Ikena Oncology, Inc. (IKNA) News
Filter IKNA News Items
IKNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IKNA News From Around the Web
Below are the latest news stories about IKENA ONCOLOGY INC that investors may wish to consider to help them evaluate IKNA as an investment opportunity.
Broker Revenue Forecasts For Ikena Oncology, Inc. (NASDAQ:IKNA) Are Surging HigherIkena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will have a reason to smile today, with the analysts making... |
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial ResultsFavorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions Encouraging signs of clinical activity and tumor shrinkage in multiple patients with difficult-to-treat epithelioid hemangioendothelioma (EHE) during dose escalation Additional IK-930 clinical data update planned for the second half of 2024; increased focus on enrollment of targeted populations i |
Ikena Oncology to Present at Multiple November 2023 Investor ConferencesBOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November. Details are as follows: Stifel Healthcare Conference, November 14-15, 2023One-on-One Investor Meetings November 14, 2023Presentation: November 14, 2023 at 1:50pm EST Jefferies London Healthcare Conference, Novemb |
Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Ikena Oncology to Participate in September 2023 Investor ConferencesBOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY. Details are as follows: Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023One-on-One Investor Meetings September 11, 2023Fireside Chat: Monday, September 11, 2023, at 3:35pm ETWebca |
Downgrade: Here's How Analysts See Ikena Oncology, Inc. (NASDAQ:IKNA) Performing In The Near TermThe latest analyst coverage could presage a bad day for Ikena Oncology, Inc. ( NASDAQ:IKNA ), with the analysts making... |
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue EstimatesIkena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 8.33% and 44.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate UpdateInitial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by year end 2023 Underwritten public offering and acquisition of Pionyr add over $80M to balance sheet BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announce |
The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stakeIkena Oncology is set to acquire a South San Francisco startup after Gilead Sciences waived its exclusive option to buy the company in March. Plus other life sciences news you may have missed. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with a look at all of the biggest pre-market stock movers worth keeping an eye on for Tuesday! |